Welcome to the May 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on such topics as the recent approval of a JAK2 RGQ PCR kit to evaluate suspected polycythemia vera, the management of venous thromboembolism in myeloproliferative neoplasms, and insight into how downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.
This month I'd like to highlight Chapter 4 of the expert video roundtable I moderated, as it discusses the importance of monitoring for polypharmacy and drug interactions as a means to enhance patient medication adherence.
Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus